Rivastigmine tartrate
Rivastigmine tartrate (SDZ-ENA 713) is a centrally-acting, reversible cholinesterase inhibitor used in dementia research for Alzheimer's and Parkinson's diseases. Its application extends to in vitro enzyme assays and in vivo models to study cognitive enhancement and neuroprotection.
Product Specifications
CAS Number
129101-54-8
Product Name Alternative
SDZ-ENA 713, SDZ-ENA-713, SDZ-ENA713, Rivastigmine, Rivastigmine tartrate, Rivastigmine Tartrate, Inhibitor, inhibit, orally, Parkinson's, parasympathomimetic, ENA 713, ENA713, ENA-713, disease, ChE, Cholinesterase (ChE), cholinesterase, cholinergic, BBB, BChE, butyrylcholinesterase, Alzheimer's, AChR, AChE, acetylcholinesteras
Field of Research
Neuroscience, Pharmacology & Drug Discovery
Purity
98.00% (May vary between batches)
Solubility
H2O:73 mg/mL (182.3 mM) ; DMSO:39 mg/mL (97.4 mM) ; Ethanol:74 mg/mL (184.8 mM)
Smiles
O[C@H] ([C@@H] (O) C (O) =O) C (O) =O.CCN (C) C (=O) Oc1cccc (c1) [C@H] (C) N (C) C
Molecular Formula
C14H22N2O2·C4H6O6
Molecular Weight
400.43
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
